SCHEMBL17766372

SCHEMBL17766372

Cc1cc(-c2ccc3c(oc(=O)n3C)c2C2CC2)ccc1NC(=O)c1c(F)cccc1F

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.42
▸ IL2 P60568 10/20 0.42
▸ TNF P01375 1/20 0.39
▸ STIM1 Q13586 1/20 0.39
▸ ORAI1 Q96D31 1/20 0.39
▸ BRPF1 P55201 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ GAA P10253 2/20 0.35
▸ CHRNA7 P36544 1/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ KDM1A O60341 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ THRB P10828 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16362417 0.87 IL2 (0.50) MAPTIL2TNFSTIM1ORAI1
SCHEMBL17766391 0.84 IL2 (0.45) MAPTIL2TNFSTIM1ORAI1
SCHEMBL16362393 0.83 IL2 (0.45) MAPTIL2TNFSTIM1ORAI1
SCHEMBL16362399 0.81 IL2 (0.53) MAPTIL2TNFSTIM1ORAI1
SCHEMBL17766358 0.81 IL2 (0.49) MAPTIL2TNFSTIM1ORAI1
SCHEMBL17766348 0.79 CRACR2A (0.40) MAPTIL2TNFSTIM1ORAI1
SCHEMBL16362395 0.78 CRACR2A (0.47) MAPTIL2TNFSTIM1ORAI1
SCHEMBL16362394 0.78 IL2 (0.51) MAPTIL2TNFSTIM1ORAI1
SCHEMBL16362421 0.77 MEN1 (0.44) MAPTMEN1KMT2ACHRNA7KCNH2
SCHEMBL17766368 0.74 IL2 (0.44) IL2TNFSTIM1ORAI1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US claimed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US claimed
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-9725463-B2 Substituted heterocyclic compounds as CRAC modulators LUPIN LIMITED (IN) 2017-08-08 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS LUPIN LIMITED (IN) 2016-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145268-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS RYR2, NR2C2, CACNA1E MAPT 4544/4885IL2 2831/4885TNF 3546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback